Drug resistance mutations to NNRTI were detected in 19 out of 22 ( 86.3 % ) and dual-class resistance to nucleoside reverse transcriptase inhibitor ( NRTI ) and NNRTI in 15 out of 27 ( 68.2 % ) of NVP failing patients .